Advertisement|Remove ads.

Shares of C4 Therapeutics, Inc. (CCCC) jumped 5% higher in pre-market trading on Thursday, after the company expanded its partnership with Swiss pharmaceutical company Roche to develop cancer treatments.
C4 Therapeutics said the new collaboration will focus on developing emerging cancer treatments using a degrader-antibody conjugate (DAC) and targeted protein degradation (TPD) processes. As part of the agreement, C4 Therapeutics and Roche will work together on two programs to develop DAC therapies targeting undisclosed cancer indications.
C4 Therapeutics will receive a $20 million upfront payment and could earn over $1 billion in milestone payments, along with tiered royalties on future sales.
Get updates to this story on Stocktwits.
For updates and corrections, email newsroom[at]stocktwits[dot]com.